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Background: Cardiovascular disease (CVD) primary prevention is guided by risk-prediction tools, but 
these rarely account for the risk of dying of other conditions (competing mortality risk).  
Methods: Retrospective population cohort study to externally validate the UK-recommended QRISK3 
CVD risk-prediction tool in Clinical Practice Research Datalink data. QRISK3 predicted 10-year CVD 
risk was compared to observed 10-year risk in the whole population and important subgroups. 
QRISK3 discrimination and calibration was examined with and without account for competing risks. 
Findings: 1,484,597 women with 42,451 incident CVD events (4.9/1000 person-years follow-up), and 
1,420,176 men with 53,066 incident CVD events (6.7/1000) were included, with median follow-up of 
5.0 years. Non-CVD death rose markedly with age (eg 0.4% of women and 0.5% of men aged 25-44 
had non-CVD death vs 20.1% and 19.6% aged 75-84). QRISK3 discrimination in the whole population 
was excellent (Harrell’s C=0.865 in women, 0.834 in men) but was poor in important subgroups (eg 
C<0.65 in all subgroups aged 65+). Ignoring competing risks, QRISK3 calibration in the whole 
population and in younger people was excellent, but there was significant over-prediction in older 
people. Accounting for competing risks, QRISK3 systematically over-predicted CVD risk, particularly 
in older people, and in people with high comorbidity.  
Interpretation: QRISK3 performs well at whole population level when ignoring competing mortality 
risk. It performs considerably less well in important subgroups including older people and people 
with comorbidity, and less well again after accounting for competing mortality risk.  
Funding: National Institute for Health Research HS&DR Programme 15/12/22  
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Research in Context 
Evidence before this study 
Guidelines for the primary prevention of cardiovascular disease (CVD) usually recommend risk-
stratified treatment, where decisions to start long-term medication to prevent future CVD events are 
guided by estimation of CVD risk with treatment offered if patients exceed a particular risk 
threshold. Recommended risk-prediction tools vary by country, reflecting differences in CVD risk 
factors and incidence. The recommended risk-prediction tool in the UK is QRISK, but two criticisms 
of recommended tools are that (1) They often do not predict risk well in older people and people 
with multimorbidity; and (2) They do not account for competing mortality risk (the risk of dying from 
non-CVD causes). We searched Pubmed from inception to 8/1/21 for observational studies 
examining competing mortality risks in people with CVD or in the context of incident CVD risk-
prediction. Estimated over-estimation of rates of CVD during follow-up has been found in the 
context of incident (first ever) CVD in the whole general population and high-risk populations such as 
people with atrial fibrillation, and of further CVD-related events in people with established CVD. The 
degree of over-estimation of CVD varies with the population, and is believed to be higher in older 
people where competing mortality risk is higher but is not usually taken into account by CVD-risk 
prediction tools. 
Added value of this study 
This external validation of the QRISK3 CVD risk-prediction tool found excellent discrimination and 
very good calibration at whole general population level. Discrimination and calibration were poor to 
moderate in older people and in people with high numbers of co-existing long-term conditions (‘high 
comorbidity’), particularly after accounting for competing mortality risks and there was systematic 
over-prediction in older people and in people with high comorbidity. 
Implications of all the available evidence 
CVD risk-prediction models need to be validated in older people and in people with high 
comorbidity. Better CVD risk-prediction models are needed to stratify people potentially eligible for 
primary preventive treatments. Clinicians should consider competing mortality risks and non-CVD 
life expectancy when discussing statin initiation for primary prevention with older people and people 




Cardiovascular disease (CVD) remains a major cause of morbidity and mortality worldwide despite 
falling incidence in most developed countries. Guidelines for the primary prevention of CVD usually 
recommend the use of risk-prediction tools to target treatment for people above a specified 
threshold of predicted risk. There has been a progressive reduction in the risk threshold 
recommended in relation to statin prescription for primary prevention. In England and Wales, the 
10-year CVD risk threshold at which treatment is recommended changed from 20% to 10% in 2014,1 
compared to a 7.5% threshold in current US guidelines.2 These reductions reflect both increasing 
evidence of statin effectiveness for primary prevention, and falling prices making statins more cost-
effective at lower levels of baseline risk (and therefore lower levels of expected absolute benefit). 
However, age is the most important predictor of CVD risk, so most people will exceed these lower 
thresholds at some point in early old age irrespective of other risk factors. The implications of 
effectively recommending medication for all older people has proved controversial.3  
Risk-stratified guideline recommendations rely on being able to accurately predict the risk of CVD 
events. Risk-prediction tools recommended in different countries vary, reflecting variation in CVD 
risk factors and incidence in different countries. In England and Wales, NICE recommend the QRISK2 
risk-prediction tool,1 which has been internally and externally validated in UK primary-care datasets, 
and found to have excellent discrimination and calibration at whole population level.33-5 A new 
version of the QRISK tool (QRISK3) has been derived and internally validated using the same 
methodology in the QRESEARCH database. The main changes in QRISK3 were to add a number of 
new conditions to the prediction equation.4 In QRISK3 internal validation in the original dataset, 
overall model discrimination was excellent, and calibration excellent in younger people and very 
good in older people,4 but external validation is required before recommending any prediction tool 
for routine use.5,6,7  
However, there are additional concerns about risk-prediction that are not directly addressed by 
conventional external validation. In particular, people who are very likely to die from non-CVD 
conditions may have little potential benefit from statins but at least some risk of harm from 
treatment. The issue is one of competing risk, which in this context arises when an individual is at 
risk of dying from conditions other than CVD. These are obvious at the extreme - taking a statin is 
clearly futile in someone at the very end of life. However, even smaller levels of competing risk can 
lead to systematic over-prediction of CVD risk in people at higher risk of dying from another cause, 
including older people and those with multimorbidity.8,9 This is because survival analyses where data 
are censored usually assume that those lost to follow-up have the same risk of the outcome as those 
who remain in follow-up (for example, if using the Kaplan-Meier estimator). This assumption is 
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clearly incorrect if someone dies of another condition (competing mortality) since a dead person 
cannot experience a CVD event.10 The aim of this analysis was to externally validate QRISK3 and 
examine the effect of competing risk on predictive performance.   
Methods 
Data source and population. We externally validated QRISK3 in Clinical Practice Research Datalink 
(CPRD) Gold),11,12 which is non-overlapping with the derivation dataset, although similar in its 
inclusion of linked primary care, hospital and mortality data. To be included, patients had to: be 
permanently registered with a general practice contributing up-to-standard data for at least one 
year and with linkage to Hospital Episode Statistics discharge and Office of National Statistics 
mortality data; be aged ≥25 years and <85 years with no prior history of CVD; and have no history of 
prior statin treatment. Cohort entry was the latest of these dates on or after 01/01/04. Cohort exit 
was the date of the earliest of: first CVD event; death; prescription of a statin; deregistration from 
the general practice; date of the last data collection from the practice; or the end of the study on 
31/3/16. All outcomes and predictors are as recorded during routine clinical care, and are therefore 
recorded blind to the study hypothesis. The study size is determined by the data available in CPRD 
which was considered sufficient,5 and no formal power calculation was done.5 
Outcomes. A first CVD event was defined as the earliest recording of any fatal or non-fatal coronary 
heart disease (CHD), ischaemic stroke, or transient ischaemic attack. Fatal CVD events were 
identified from ICD-10 codes recorded in Office of National Statistics death registration. Non-fatal 
events were identified either in GP EHRs (using Read codes, the standard coding system used in UK 
general practice) or Hospital Episode Statistics (HES) discharge diagnoses (ICD-10 codes). Read and 
ICD-10 codes defining outcomes are those used in QRISK3 derivation,4 and are listed in 
supplementary table S1  
Prediction model. We implemented the published QRISK3-2017 prediction model (under GNU Lesser 
General Public Licence v3) with some exceptions, namely: (1) We chose a later cohort entry date 
(1/1/04 rather than 1/1/98); (2) We handled cholesterol missingness differently (if no values were 
available at baseline, QRISK3 derivation allowed cholesterol values from after the index date to be 
used if they were before any event; we only included values recorded before the index date to avoid 
using future information in prediction); and (3) We evaluated the Townsend deprivation score as the 
median of the vigintile (equal 20th) of score that an individual lived in, as individual values were not 




Comorbidity. For each patient at baseline, we additionally calculated a modified Charlson 
Comorbidity Index (mCCI) based on primary care Read codes (modified in that CVD could not 
contribute to the score as all participants are CVD-free at baseline).13 mCCI was not used in 
prediction, but was used to stratify the population to examine discrimination and calibration by 
mCCI score (grouped into 0, 1, 2, and 3+).  
Missing data. Supplementary table S5 details how missing data were treated for all variables, and 
the extent of missingness. As with QRISK3 derivation, patients with missing Townsend deprivation 
score were excluded from the cohort, those with missing ethnicity were assumed to be white, and 
multiple imputation was used for missing body mass index (BMI), total cholesterol:HDL cholesterol 
ratio (TC:HDL), systolic blood pressure (SBP), SBP variability, and smoking status. For the variables 
listed in supplementary table S5, Multivariate Imputation by Chained Equations14 was used to 
generate five imputed datasets. Analyses of these datasets were combined using Rubin’s rules15 to 
give summary point estimates with confidence limits that reflect the added uncertainty associated 
with imputing missing values.  
Statistical methods. The 10-year risk of suffering a cardiovascular event was calculated for each 
patient using the published QRISK3 equation without recalibration. The performance of the risk 
score was assessed by examining discrimination and calibration.  
Discrimination is the ability of the risk score to differentiate between patients who experience the 
event of interest during the study and those who do not. We used the truncated version of Harrell’s 
C-statistic to only include pairs where the earliest survival time is no later than 10 years after entry. 
Where there is considerable censoring, Harrell’s C-statistic may be optimistic.  We therefore carried 
out a sensitivity analysis using a weighted C-statistic accounting for probability of censoring.16 A C-
statistic of 0.5 indicates discrimination that is no better than chance, whereas a C-statistic of 1 
indicates perfect discrimination. Two additional measures of discrimination were calculated, the D 
statistic of Royston and Sauerbrei (based on the separation in event free survival between those 
patients with predicted risk scores above and below the median; higher values indicate greater 
discrimination),17 and a related R-squared statistic estimating explained variation in the context of 
censored survival data.18   
Calibration refers to how closely the predicted and observed probabilities agree at group level. This 
was assessed for equally-sized groups of participants ranked by predicted risk. Calibration of the risk 
score predictions was assessed by plotting observed proportions versus predicted probabilities. Plots 
were generated separately by sex, for all patients and for pre-specified subgroups of age and mCCI 
based on summary statistics pooled across the imputed datasets.  
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The following summary statistics and their standard errors were obtained by decile of predicted risk 
score and for each imputed dataset in turn: non-parametric measures of observed risk or 
proportions of patients with a CVD event, the Kaplan-Meier estimator (the conventional measure 
ignoring competing risks) and the Aalen Johansen estimator (an extension to allow for competing 
events, non-CVD death in this case),19 and the mean predicted risk score. All models were fitted in R-
4.0.0 and STATA 11.2. 
Findings 
There were 1,648,746 women aged 25-84 with linkage to HES and ONS, of whom 164,129 (10.0%) 
were excluded because of prior CVD (4.7%), prior statin prescribing (5.1%), or missing deprivation 
score (0.2%). There were 1,621,535 men aged 25-84 with linkage to HES and ONS, of whom 201,359 
(12.4%) were excluded because of prior CVD (6.9%), prior statin prescribing (5.3%) or missing 
deprivation score (0.2%). 1,484,597 women and 1,420,176 men were therefore included in the 
study.  
Baseline characteristics of the study population are shown in table 1, compared to the QRISK3 
internal validation cohort.4 Across most characteristics, the two cohorts were similar, but in this 
study the prevalence of treated hypertension and current smoking was higher, and recording of a 
family history of CHD was lower. Supplementary table S5 details missing data, which was less 
frequent in this study for ethnicity, similar for systolic blood pressure and body mass index, and 
more frequent for total cholesterol:HDL cholesterol ratio, systolic blood pressure variability, and 
smoking status.  
There were 42,451 incident cases of CVD observed in women in 8,594,620 years of follow-up (4.9 
[95%CI 4.89-4.99] per 1000 person-years), compared to 53,066 incident cases in men in 7,896,704 
years of follow-up (6.7 [95%CI 6.66-6.78] per 1000 person-years). CVD incidence rose progressively 
with age (supplementary table S6), and was moderately lower than that observed in QRISK3 
derivation4.  
Follow up time and censoring. Median follow up in the whole cohort was 5.0 years, with 22.1% of 
patients still in the cohort and CVD event-free at 10 years. Table 2 shows the status of all patients at 
10 years. In women, CVD events occurred in 2.6% by 10 years and non-CVD deaths in 2.8%, 
compared to 3.5% and 2.7% respectively in men. Censoring due to statin initiation was more 
common (8.6% of women, 10.2% of men), but almost two-thirds of both men and women were 
censored due to deregistration or by <10 years follow-up before the end of the study on 31/3/16. 
Patterns of censoring were markedly different by age and by modified Charlson Comorbidity Index 
(mCCI). Censoring due to statin initiation rapidly increased with age, peaking in 65-74 year olds 
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where approximately a quarter of men and women started statins for primary prevention during 
follow-up. Censoring due to deregistration or having less than 10-years follow-up by the end of study 
was markedly more common in younger people, whereas censoring due to non-CVD death was 
markedly more common in older people. Similar patterns to age were seen with mCCI 
Discrimination. Overall discrimination was excellent and very similar to QRISK3 internal validation4 
(for women, Harrell’s C-statistic=0.865 external validation vs 0.880 QRISK3 internal validation, 
D=2.43 vs 2.49, R2 58.5% vs 59.6%; for men Harrell’s-C 0.834 vs 0.858, D=2.10 vs 2.26, R2=51.3% vs 
55.0%). However, discrimination varied markedly within the age-group and mCCI categories, with 
discrimination being best in the youngest (25-44 years) and least multimorbid (mCCI=0) groups, and 
worst in the oldest (75-84 years) and most multimorbid (mCCI=3+) groups. For example, in women 
aged 75-84, Harrell’s C statistic=0.611, and for men aged 75-84, Harrell’s C-statistic=0.585, 
representing poor discrimination, with only moderate discrimination observed in women and men 
aged 65-74. Sensitivity analysis using a censoring-adjusted C-statistic found somewhat lower 
discrimination, but did not alter the overall interpretation (supplementary table S7) 
Calibration in women. Figure 1 and Supplementary Figures S1-S2 show calibration plots for women. 
Ignoring competing mortality risks (left-hand plots), calibration is excellent for all women, and for 
women aged 25-44 years. However, QRISK3 progressively over-predicted CVD risk in older age-
groups. Stratified by mCCI, there is evidence of some over-prediction in the least comorbid 
(mCCI=0), but of poor calibration and under-prediction in those with high comorbidity (mCCI≥3).  
When competing mortality risks are accounted for (right-hand plots), there is over-prediction of risk 
at higher levels of predicted CVD risk in all women. The same pattern of increasing over-prediction 
with increasing age is observed, but with greater magnitude and calibration is poor in older age 
groups. Although there is some observed under-prediction of risk in those with mCCI≥3 for those at 
lower predicted CVD risk, the overall pattern is of over-prediction of CVD risk which increases with 
comorbidity, and calibration is poor in the most co-morbid (mCCI=2 and mCCI≥3).  
Calibration in men. Figure 2 and Supplementary Figures S3-S4 show calibration plots for men. 
Ignoring competing mortality risks (left-hand plots), calibration is excellent for all men although with 
somewhat greater over-prediction at higher levels of predicted CVD risk than in women. Calibration 
is excellent for men aged 25-44 years, but QRISK3 progressively over-predicted CVD risk in older age-
groups. Stratified by mCCI, there is evidence of some over-prediction in the least comorbid 
(mCCI=0), but of poor calibration and under-prediction in those with high comorbidity (mCCI≥3).  
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When competing mortality risks are accounted for (right-hand plots), there is over-prediction of risk 
at higher levels of predicted CVD risk in the whole population. Calibration is poor with large over-
prediction in older age-groups. Although there is some observed under-prediction of risk in those 
with mCCI≥3 for those at lower predicted CVD risk, the overall pattern is of over-prediction of CVD 
risk which increases with comorbidity, and calibration is poor in the most co-morbid (mCCI=2 and 
mCCI≥3). 
Discussion 
This external validation study finds that at whole population level, QRISK3 has excellent 
discrimination (the ability of the model to distinguish people at higher or lower risk; women c=0.86, 
men c=0.83), but discrimination was only poor to moderate in people aged 75-84 (women c=0.61, 
men c=0.58) and moderate to good in people with high levels of comorbidity (mCCI≥3; women 
c=0.74, men c=0.70). Calibration (the extent to which predicted and observed event rates are 
similar) was excellent in the whole population when ignoring competing mortality risks but there 
was evidence of systematic under-prediction after competing risks were accounted for. Calibration 
was considerably worse in older people and in those with higher levels of comorbidity where QRISK3 
systematically over-predicted risk, particularly after competing mortality risks were accounted for.  
At whole population level, the QRISK3 CVD risk-prediction model does appropriately sort the whole 
population into groups with varying levels of cardiovascular risk (with some small over-prediction), 
but the model performs relatively poorly in older people and people with high comorbidity, in part 
because of high competing mortality risk.  
Strengths of the study include conduct consistent with methodology recommendations,6,20 
comprehensive detailing of all code sets used to facilitate replication, and explicit consideration of 
prediction in subgroups and competing mortality risks.  
Limitations largely reflect problems common to all studies using routine GP data, including the 
original QRISK3 derivation.21 The prevalence of missing data for key predictors is high. Like the 
original QRISK3 derivation, we used multiple imputation for missing data, but in this context the 
assumption that data are missing at random is a strong one, but balanced against the use of 
representative population data. All recent QRISK models have also used 1/1/98 as the index date 
(the earliest that patients can enter the study). Much observed follow-up in model derivation is 
therefore historical,21 and there is a trade-off between using an index date in the distant past (when 
CVD incidence is higher than now) or a more recent index date (in which case more patients are 
excluded because of prior statin use). Our choice of a more recent index date may partly explain why 
QRISK3 is observed to over-predict in our validation. Deriving clinical prediction tools on increasingly 
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historical data is likely biased,21 but using more recent data with greater rates of prior statin 
initiation may also be biased. There is no clearly optimal resolution to this dilemma. Finally, loss to 
follow-up before a CVD event was common which is relevant to model assumptions about censored 
patients. We specifically examined the impact of censoring due to non-CVD death, but it is also an 
assumption that those who deregister from practices have the same CVD risk as those who do not. 
That seems likely to be true for younger people, but less so for older people where change of 
address will be more commonly driven by change in health status (eg moving to sheltered housing or 
a care home).  
Previous external validations of previous QRISK tools have also found excellent discrimination and 
calibration at the whole population level when competing mortality risks were ignored (ie answering 
the question ‘what is the risk of CVD assuming that this person does not die of anything else in the 
next 10 years?’).3 QRISK3 therefore ‘works’ at whole population level when considered in its own 
terms (ignoring competing risks), but even so, discrimination and calibration were poor in those 
aged 75-84 years, and only moderate in those aged 65-74 years and in those with the highest levels 
of comorbidity (mCCI=3).  
There was greater over-prediction at whole population level once competing mortality risk was 
accounted for (ie answering the question ‘what is the risk of CVD allowing for the risk of this person 
dying of something else first?’). Calibration was notably poorer once competing risk was accounted 
for, particularly in older and more comorbid patients. These findings are consistent with other 
studies examining the impact of competing risks on estimated CVD risk in people without 
CVD,9,10,22,23 with established CVD,24 and in other contexts including stroke risk in people with atrial 
fibrillation.25,26  QRISK2 has also been shown to systematically over-predict CVD risk in a 
contemporary population of people with type 2 diabetes, with increasingly poor discrimination with 
increasing age, highlighting that good performance at whole population level does not necessarily 
mean good performance in important subgroups.27  
At population level, QRISK3 does segment the population into groups which largely have the risk of 
CVD predicted (supporting its use to guide risk-stratified treatment decisions). However, this overall 
assessment of prediction performance is largely driven by good performance in younger people with 
fewer co-existing long-term conditions. For older people and people with more long-term 
conditions, prediction is poor to fair, particularly when competing risks are accounted for. The lower 
levels of over-prediction in other age and comorbidity groups will also sometimes change treatment 
recommendations in younger and less comorbid people. Similar issues likely apply to other CVD risk-
prediction models which do not account for competing risk. We believe that predicting CVD events 
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without accounting for risk of death from other causes is misleading in people at high risk of non-
CVD death. Clinicians should therefore carefully consider life expectancy related to other conditions 
when discussing long-term cardiovascular primary preventive treatment.  
There are several areas where further research would be beneficial. CVD causes a large proportion 
of deaths, which will reduce the impact of competing risks. There is a need for further studies 
examining the impact of competing risk when predicting less commonly fatal conditions, where the 
impact on predictive performance is likely to be greater. It is also uncertain whether a better 
approach to CVD prediction would be to create separate models for important subgroups of age and 
comorbidity (as is already done for men and women). The relative merits of omnibus vs smaller 
subgroup models needs research, as does better quantifying the uncertainty at individual level of 
risk-prediction tools which perform well at population level.28 A weakness of existing UK primary 
care datasets in deriving risk-prediction rules is the large loss to follow-up where there is a long 
time-horizon for risk-prediction. This study has examined the impact of competing risk, but other 
loss to follow-up due to practice deregistration is likely to create over-prediction in at least some 
population subsets. External validation in large geographical populations with less loss to follow-up 
(such as SAIL Databank in Wales) would be valuable, as would larger-scale data federation to derive 
and validate new risk-prediction tools for comparison with QRISK3 and other prediction models.21 
In conclusion, QRISK3 performs well at whole population level, but systematically over-predicts CVD 
risk in older people and people with high comorbidity. Clinicians should consider broader impacts on 
life expectancy when discussing statin initiation for primary prevention in older people and people 
with high comorbidity in whom CVD risk is likely over-predicted.  Better calibrated prediction models 







The study was conceived of and designed by BG, KP, DRM, PTD, KP and AT who obtained the 
funding. All authors contributed to study design and interpretation. SL, BG, DRM and PTD led data 
management and SL led analysis supported by BG, DRM and PTD. SL and BG drafted the paper, 
which all authors reviewed and edited. SL, BG and DRM verified the underlying data.  
Competing interests 
None to declare 
Ethics approval 
The study was approved by the Clinical Practice Research Datalink Independent Scientific Advisory 
Committee protocol 16_248 
Funding 
This study/project is funded by the National Institute for Health Research (NIHR) Health Services and 
Delivery Research Programme (project reference 15/12/22). The views expressed are those of the 
authors and not necessarily those of the NIHR or the Department of Health and Social Care. The 
authors had full and sole access the data, and the funder had no role in the conduct of the research 
or the decision to publish.  
Data sharing 
The data controller is the Clinical Practice Research Datalink (CPRD), and under the data licence 
granted, the authors are not allowed to share data. Researchers can apply to CPRD directly for 




Table 1: Baseline data in external validation cohort and in original QRISK3 internal validation cohort4 
 Women external 
validation cohort 
N=1484597 
Women original QRISK3 
internal validation cohort 
N=1360457 
Men external validation 
cohort 
N=1420176 
Men original QRISK3 
internal validation 
N=1310841 
Mean (SD) Age (years) 46.0 (15.3) 43.3 (15.3) 44.8 (13.9) 42.6 (13.8) 
Mean (SD) Body mass index 25.9 (5.7) 25.4 (5.1) 26.6 (4.7) 25.9 (4.2) 
Mean (SD) Total cholesterol:HDL cholesterol ratio 3.7 (1.1) 3.6 (1.2) 4.4 (1.3) 4.4 (1.3) 
Mean (SD) Systolic blood pressure (mmHg) 125.4 (18.0) 123.1 (18.1) 131.1 (16.2) 128.8 (16.2) 
Mean (SD) Systolic blood pressure variability 10.0 (5.7) 9.3 (6.1) 10.3 (6.2) 9.9 (6.8) 
Ethnicity No. (%)     
White or not recorded 1363146 (91.8) 1218391 (89.6) 1336,221 (94.1) 1171281 (89.4) 
Indian 22488 (1.5) 23146 (1.7) 15322 (1.1) 26479 (2.0) 
Pakistani 9550 (0.6) 10919 (0.8) 6647 (0.5) 14787 (1.1) 
Bangladeshi 2594 (0.2) 8738 (0.6) 2145 (0.2) 11914 (0.9) 
Other Asian 13697  0.9) 17078 (1.3) 9973 (0.7) 15966 (1.2) 
Black Caribbean 9505 (0.6) 13142 (1.0) 6687 (0.5) 10642 (0.8) 
Black African 18804 (1.3) 27678 (2.0) 12822 (0.9) 25251 (1.9) 
Chinese 6739 (0.5) 8992 (0.7) 3503 (0.2) 6098 (0.5) 
Other 38074 (2.6) 32373 (2.4) 26829 (1.9) 28423 (2.2) 
Smoking status No. (% of non-missing)     
Non-smoker 707774 (59.8) 706671 (51.9) 478671 (49.0) 512252 (39.1) 
Former smoker 217404 (18.4) 194545 (14.3) 216883 (22.2) 196459 (15.0) 
Light smoker  85277 (7.2) 154565 (11.4)  75260 (7.7) 177693 (13.6) 
Moderate smoker 111690 (9.4) 74933 (5.5) 112411 (11.5) 84914 (6.5) 
Heavy smoker  62236 (5.3) 38218 (2.8)  93457 (9.6) 64107 (4.9) 
FH of CHD in first degree relative <60 years 97624 (6.6) 164023 (12.1) 75237 (5.3) 123039 (9.4) 
Type 1 diabetes 3752 (0.3) 3351 (0.2) 4843 (0.3) 3932 (0.3) 
Type 2 diabetes 17022 (1.1) 15872 (1.2) 21077(1.5) 19318 (1.5) 
Treated hypertension 115944 (7.8) 77694 (5.7) 82768 (5.8) 56920 (4.3) 
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Rheumatoid arthritis 12702 (0.9) 15139 (1.1) 4724 (0.3) 7055 (0.5) 
Atrial fibrillation 8199 (0.6) 5229 (0.4) 10620 (0.7) 6874 (0.5) 
Chronic kidney disease (stage 3, 4 or 5) 6918 (0.5) 6949 (0.5) 5659 (0.4) 4232 (0.3) 
Migraine 117692 (7.9) 89504 (6.6) 41471 (2.9) 36141 (2.8) 
Corticosteroid use 20674 (1.4) 31775 (2.3) 11824 (0.8) 18634 (1.4) 
HIV/AIDS 289 (0.02) 1595 (0.1) 445 (0.03) 2945 (0.2) 
Systemic lupus erythematosus 1725 (0.1) 1349 (0.1) 165 (0.01) 134 (0.0) 
Atypical antipsychotic use 8469 (0.6) 6268 (0.5) 8336 (0.6) 6597 (0.5) 
Severe mental illness 110799 (7.5) 94724 (7.0) 57264 (4.0) 57830 (4.4) 
Erectile dysfunction diagnosis or treatment N/A N/A 39,264 (2.8) 31136 (2.4) 
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Table 2: Follow-up and censoring events at ten years 
 No entering 
study cohort 
Non-fatal CVD  
No. (%) 
CVD death  
No. (%) 
Censored because 
non-CVD death  
No. (%) 
Censored because 
started statin  
No. (%) 
Censored because 
deregistered or end 
of study (31/3/16) 
before ten years FU 
No. (%) 
At least ten years 
follow-up 
No. (%) 
All women  1484597 34047 (2.3) 5001 (0.3) 40839 (2.8) 128183 (8.6)  926832 (62.4) 349695 (23.6) 
All men 1420176 42675 (3.0) 6471 (0.5) 38226 (2.7) 145482 (10.2) 895421 (63.1) 291901 (20.6) 
Women        
Aged 25-44 813157 3064 (0.4) 124 (0.0) 3250 (0.4) 14076 (1.7) 612336 (75.3) 180307 (22.2) 
Aged 45-64 465484 10825 (2.3) 671 (0.1) 11101 (2.4) 68552 (14.7) 242367 (52.1) 131968 (28.4) 
Aged 65-74 121267 8958 (7.4) 1142 (0.9) 9454 (7.8) 32139 (26.5) 43549 (35.8) 26205 (21.6) 
Aged 75-84 
 
84689 11200 (13.2) 3064 (3.6) 17034 (20.1) 13416 (15.8) 28760 (34.0) 11215 (13.2) 
mCCI        
0 1187965 21890 (1.8) 2908 (0.2) 22287 (1.9) 86730 (7.3) 769100 (64.7) 285050 (24.0) 
1 229651 7981 (3.5) 1273 (0.6) 9272 (4.0) 28553 (12.4) 128966 (56.2) 53606 (23.3) 
2 51295 2956 (5.8) 567 (1.1) 6211 (12.1) 9787 (19.1) 22698 (44.2) 9076 (17.7) 
3+ 15686 1220 (7.8) 253 (1.6) 3069 (19.6) 3113 (19.8) 6068 (38.7) 1963 (12.5) 
Men        
Aged 25-44 815950 5659 (0.7) 461 (0.1) 4205 (0.5) 25050 (3.1) 614615 (75.3) 165960 (20.3) 
Aged 45-64 458384 19595 (4.3) 2105 (0.5) 12211 (2.7) 86437 (18.9) 234266 (51.2) 103770 (22.6) 
Aged 65-74 96404 9870 (10.2) 1607 (1.7) 9572 (9.9) 26821 (27.8) 31910 (33.1) 16624 (17.2) 
Aged 75-84 
 
49438 7551 (15.3) 2298 (4.6) 12238 (24.8) 7174 (14.5) 14630 (29.6) 5547 (11.2) 
mCCI        
0 1173065 30524 (2.6) 4269 (0.4) 22906 (2.0) 104942 (8.9) 763831 (65.1) 246593 (21.0) 
1 201200 8228 (4.1) 1368 (0.7) 7903 (3.9) 29919 (14.9) 113921 (56.6) 39861 (19.8) 
2 34665 2814 (8.1) 549 (1.6) 4758 (13.7) 8088 (23.3) 13994 (40.4) 4462 (12.9) 
3+ 11246 1109 (9.9) 285 (2.5) 2659 (23.6) 2533 (22.5) 3675 (32.7) 985 (8.8) 
mCCI: modified Charlson Comorbidity Index
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Table 3: Discrimination and model fit 
 Women   Men   
 Harrell’s C D R-squared Harrell’s C D R-squared 











































































Figure 1: Calibration in women without accounting for competing risks (left hand) and accounting for 
competing risks (right hand) 
Women - not accounting for competing risks* Women - accounting for competing risks# 
1a: Overall calibration 
 
1b: Overall calibration 
 
1c: Calibration by age group 
 
1d: Calibration by age group 
 
1e: Calibration by Charlson  Comorbidity Index 
 
1f: Calibration by Charlson Comorbidity Index 
 
* Observed risk is based on the Kaplan-Meier estimator, which does not account for competing mortality risk. 
# Observed risk is based on the Aalen-Johansen estimator, which accounts for competing mortality risk  
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Figure 2: Calibration in men without accounting for competing risks (left hand) and accounting for competing 
risks (right hand) 
Men - not accounting for competing risks* Men - accounting for competing risks# 
2a: Overall calibration 
 
2b: Overall calibration 
 
2c: Calibration by age group 
 
2d: Calibration by age group 
 
2e: Calibration by Charlson Comorbidity Index 
 
2f: Calibration by Charlson Comorbidity Index 
 
* Observed risk is based on the Kaplan-Meier estimator, which does not account for competing mortality risk. 
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